BlackRock Seeks Staking Option for iShares Ethereum Trust in New Filing
The update signals that BlackRock is aiming to go beyond simple ether (ETH) exposure and participate in Ethereum's proof-of-stake consensus system. If approved, the ETF could stake a portion of its ETH holdings through one or more trusted providers to generate additional yield.
Ether staking involves locking up tokens to help secure the network in exchange for regular payouts. Several asset managers, including Franklin Templeton and Grayscale, have also proposed staking features in their Ethereum ETF filings. The SEC delayed its first deadline to make a decision on those proposals.
U.S. regulators have yet to definitively decide whether staking services offered through an ETF would qualify as securities activity. But the inclusion of staking in the BlackRock filing reflects growing confidence that staking could eventually be part of crypto ETFs.
The SEC is widely expected to greenlight a further wave of spot crypto ETFs this year after approving similar bitcoin and ether products last year.
ETHA is currently trading at $25.42 a share and has attracted over $7.2 billion in assets since its launch in June of last year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Cantor outlines how to navigate the emerging Bitcoin treasury sector
- The amount of Bitcoin owned by companies specializing in accruing more of the cryptocurrency is anticipated to rise, according to analysts at Cantor. Many firms have recently embarked on Bitcoin buying sprees, as part of a bid to capitalize on the digital coin's soaring value and hopes for a softer regulatory backdrop. In a note, the analysts led by Brett Knoblauch said these so-called "Bitcoin treasury companies," such as MicroStrategy (NASDAQ:MSTR), Marathon Digital Holdings (NASDAQ:MARA), and CleanSpark (NASDAQ:CLSK), own or have raised capital acquire roughly 904,000 of the digital tokens. "[W]e expect that number to only continue to increase given the capital market advantages these companies have," they argued. They added that "if feels like a new Bitcoin treasury play is emerging every day," fueled by a range of factors, including retail investor enthusiasm, the relative ease of buying stocks compared to cryptocurrencies, and fewer punitive tax rules equities than on digital assets. "Financial engineering" is also seen allowing Bitcoin treasury companies to continuously grow their Bitcoin positions in the future, the analysts predicted. The trend comes as firms are trying to emulate the success of Strategy, the software group formerly known as MicroStrategy, which began building up its Bitcoin stockpile in 2020 and now owns more than $63 billion worth of the world's largest cryptocurrency. Investors have seemingly celebrated the move, with Strategy's stock up by 3,000% since 2020, mirroring a surge in Bitcoin to recent all-time highs. Last week, twenty new public firms announced crypto purchases, the Cantor analysts noted. But "not all Bitcoin treasury companies are created equal" and "some offer better risk/reward than others," they flagged. Perhaps most importantly, these companies need to be able to rake in capital, as this will help facilitate further Bitcoin purchases, the analysts said. "The amount of capital a company has access to in this space is largely driven by trading liquidity. For shares to have a relatively high amount of volume, we believe they need to have a management team that carries weight in the crypto ecosystem," they argued. Buying Bitcoin is crucial for these companies, as their ability to acquire more of the asset will likely determine their long-term performance, the analysts said. "Thus, if we look at multiple of Bitcoin net asset value, a company on a higher multiple today objectively screens more expensive, but that could be entirely justified by the market's perception that it can sustain continued Bitcoin acquisitions over the long run," they wrote. Against this backdrop, the analysts named Strategy as their top pick among Bitcoin treasury names, and initiated coverage of new players Semler Scientific and Fold Holdings with "overweight" ratings. Related articles Cantor outlines how to navigate the emerging Bitcoin treasury sector Eric Trump tweets support for Ethereum amid price rally Trump-linked World Liberty Financial coin price could 'skyrocket' says analyst Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 minutes ago
- Yahoo
ScanTech AI Files Its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission (SEC)
Company Reaffirms Commitment to Financial Transparency and Execution Discipline Atlanta, GA, July 28, 2025 (GLOBE NEWSWIRE) -- ScanTech AI Systems Inc. (the "Company" or "ScanTech AI") (Nasdaq: STAI), a leading innovator in advanced security screening technologies, today announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 (the 'Form 10-Q'), with the U.S. Securities and Exchange Commission ('SEC'). With this filing, the Company expects to resolve the deficiency relating to Nasdaq Listing Rule 5250(c)(1) for which the Company was in noncompliance as a result of not having timely filed the Form 10-Q. ScanTech AI remains committed to maintaining consistent and transparent financial disclosures moving forward. About ScanTech AI ScanTech AI Systems Inc. (Nasdaq: STAI) has developed one of the world's most advanced non-intrusive 'fixed-gantry' CT screening technologies. Utilizing proprietary artificial intelligence and machine learning capabilities, ScanTech AI's state-of-the-art scanners accurately and quickly detect hazardous materials and contraband. Engineered to automatically locate, discriminate, and identify threat materials and items of interest, ScanTech AI's solutions are designed for use in airports, seaports, borders, embassies, corporate headquarters, government and commercial buildings, factories, processing plants, and other facilities where security is a priority. For more information, visit and Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the U.S. Securities Exchange Act of 1934, as amended ('Exchange Act'), including statements regarding ScanTech AI's management team's expectations, hopes, beliefs, intentions, plans, prospects or strategies regarding the future, including Nasdaq compliance or noncompliance, possible business combinations, revenue growth and financial performance, product expansion and services. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Additionally, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing,' 'target,' 'seek' or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on the current expectations and beliefs made by the management of ScanTech AI, in light of their respective experience and their perception of historical trends, current conditions and expected future developments and their potential effect on ScanTech AI, as well as other factors they believe are appropriate under the circumstances. There can be no assurance that future developments affecting ScanTech AI will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including product and service acceptance, regulatory oversights, research and development success, and that ScanTech AI will have sufficient capital to operate as anticipated. Should one or more of these risks of uncertainties materialize, or should any of the assumptions of ScanTech AI prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Additional factors that could cause actual results to differ are discussed under the heading 'Risk Factors' and in other sections of the filings of ScanTech AI (and its predecessor, Mars) with the U.S. Securities and Exchange Commission (the 'SEC'), and in the current and periodic reports filed or furnished by ScanTech AI (and its predecessor, Mars) from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on the information available to ScanTech AI as of the date hereof, and ScanTech AI assumes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as may otherwise be required under applicable securities laws. Contact:ScanTech AI Systems White, CFOjwhite@ Investor & Media Relations Contact:International Elite Capital Inc. Annabelle Zhang +1(646) 866-7928 annabelle@
Business Wire
4 minutes ago
- Business Wire
RXST INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that the RxSight class action lawsuit – captioned Makaveev v. RxSight, Inc., No. 25-cv-01596 (C.D. Cal.) – seeks to represent purchasers or acquirers of RxSight, Inc. (NASDAQ: RXST) securities and charges RxSight as well as certain of RxSight's executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the RxSight class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or of Robbins Geller by calling 800/449-4900 or via e-mail at info@ Lead plaintiff motions for the RxSight class action lawsuit must be filed with the court no later than September 22, 2025. CASE ALLEGATIONS: RxSight is a commercial-stage medical technology company that engages in the research and development, manufacture, and sale of light adjustable intraocular lenses ('LAL') used in cataract surgery. The RxSight class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) RxSight was experiencing 'adoption challenges' and/or structural issues resulting in declines in sales and utilization; (ii) defendants had overstated the demand for RxSight's products; and (iii) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025. The RxSight class action lawsuit further alleges that on July 8, 2025, RxSight reported preliminary second quarter of 2025 financial results, revealing significant declines in Light Delivery Device ('LDD') sales, LAL utilization, and overall revenue. RxSight also lowered its full year 2025 guidance by approximately $42.5 million at the midpoint, and RxSight's CEO, defendant Ronald Kurtz, disclosed that '[a]doption challenges over the last few quarters have been a primary reason for the LDD stall,' according to the complaint. The RxSight class action lawsuit alleges that on this news, the price of RxSight stock fell nearly 38%. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired RxSight securities during the class period to seek appointment as lead plaintiff in the RxSight class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the RxSight class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the RxSight class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the RxSight class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
